Neovii is under new management
Swiss biotech firm Neovii has a new leadership team. Dr Christian Loss, formerly the company's managing director is becoming the new CEO. He will be succeeded by the former Neovii Head of Production, Sebastian Hofmann. Both have been with the company for more than ten years.
Neovii is a key producer of Grafalon, an immunosuppressive pharmaceutical used to prevent acute organ transplant rejection, and graft-versus-host disease (GVHD), which can happen after a stem cell transplant.
"We have been on the market for 40 years, making us one of the pioneers in the biotech scene in Europe" Dr Loss said. "With our team, decades of experience in clinical development and regulatory affairs, and our top technology platform, we are now taking the next step to become one of the leading biopharmaceutical companies in the global treatment of severe immune and cancer diseases."
Novant Health appoints new board member
Novant Health, a not-for-profit healthcare provider in Georgia and both Carolina states, has appointed healthcare consultant David P. King to its board of trustees.
In 2019 Forbes named King to its list of America’s Most Innovative Leaders. He has served in leadership roles at Laboratory Corporation of America Holdings (Labcorp), one of the largest medical testing laboratory and drug development businesses in the world, and was instrumental in leading the company’s transformation from a US testing laboratory to a global life sciences company. He has also served on Cardinal Health’s board of directors.
“David’s three decades of healthcare and legal experience, including expertise on healthcare innovation, policy and operations, as well as his background in M&A, enhances Novant Health’s board of trustees’ perspective as we look for opportunities to broaden our reach in the region and continue to provide remarkable, innovative patient care" Carl S. Armato, president and chief executive officer of Novant Health said.
Laguna Health hires new VP of Operations and Strategy
Laguna Health, a digital-first home recovery platform, has appointed Matthew Conboy as VP of Strategy and Operations. He will lead clinical strategy and operations, connecting sales, clinical, and product teams.
Conboy brings with him 15 years of experience from both hypergrowth healthcare startups and some of the world’s largest health insurance leaders, including Ready, and CareAllies, a subsidiary of Cigna.
Conboy’s appointment is the latest in a series of major new executive hires for Laguna, including Fortune 100 benefits strategy leaders. As the company continues to scale, Conboy will be responsible for building Laguna's multi-disciplinary clinical team, expanding its operational capabilities and leading strategic initiatives.
“I’ve seen first hand how digital tools can bridge the gap in healthcare, and I’m honoured to join the Laguna team to help further drive the adoption of their digital-first recovery platform while scaling the team to support current and new customers.”